Camlin Fine Sciences experiences a significant drop in Q4 EBITDA, declining from 594M to 212M year-on-year, accompanied by a decrease in the EBITDA margin, falling from 13.6% to just 5%.

Camlin Fine Sciences has announced that Pankaj Pandey will take over as Chief Financial Officer, starting August 2026. The appointment was confirmed during a board meeting held on May 26, 2026.

Camlin Fine Sciences has finalized its FY26 financial results with a clean audit report. The company's 33rd Annual General Meeting is scheduled for August 11, 2026. The acquisition of Vinpai resulted in an additional goodwill of INR 168.1 crores.

Camlin Fine Sciences is planning to reach a revenue target of INR 14 billion in blend segments by the fiscal year 2026-2027. The company emphasizes the importance of efficient debt management as part of their strategic focus.

Camlin Fine Sciences temporarily halts production at its diphenol plant due to challenges with raw materials and geopolitical factors. A recent fire led to a 2 crore INR loss, but the company anticipates resuming production shortly.

Camlin Fine Sciences will announce their audited financial results on May 26, 2026. Trading in the company's shares is currently suspended and will remain so until 48 hours after the results are disclosed.

Camlin Fine Sciences has announced a 13% increase in fiscal year 2025 revenue, reaching INR 857 crores compared to INR 756 crores in the previous fiscal year.

Camlin Fine Sciences has successfully acquired a significant stake (78.7%) in Vinpai at EUR 3.6 per share, indicating their commitment to the company's growth. The remaining shares are now being tendered with experts confirming that the offered price appears fair for minority shareholders.

Ashish Dandekar has unencumbered a portion of his shares in Camlin Fine Sciences Ltd as per SEBI regulations, following repayment. This has reduced the total encumbered shares to 7.78% as of April 17, 2026.

Camlin Fine Sciences has been hit with a tax demand of approximately INR 5.47 crore for the fiscal year 2023-24, primarily due to concerns over related party transactions. The company intends to lodge an appeal against this demand.

Ashish S. Dandekar, promoter of Camlin Fine Sciences, has committed 6.5 lakh shares (approximately 0.34% of the company's capital) as a pledge to Ashika Credit Capital, aiming to secure additional margin.